Sign In
Buy BCRX
$8.25
-0.0900 (-1.08%)
At Close: Jun 03, 2026
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema
09:00am, Friday, 23'rd Jan 2026
RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initi
Analyzing BioCryst Pharmaceuticals (NASDAQ:BCRX) and Prelude Therapeutics (NASDAQ:PRLD)
01:14am, Thursday, 22'nd Jan 2026
Prelude Therapeutics (NASDAQ: PRLD - Get Free Report) and BioCryst Pharmaceuticals (NASDAQ: BCRX - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contr
Campbell & CO Investment Adviser LLC Decreases Position in BioCryst Pharmaceuticals, Inc. $BCRX
04:31am, Tuesday, 20'th Jan 2026
Campbell and CO Investment Adviser LLC lessened its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 73.4% during the undefined quarter, according to the company in its most rece
BioCryst Pharmaceuticals Touts ORLADEYO Momentum, Astria Deal and 2026 Outlook at JPM Conference
02:04am, Tuesday, 13'th Jan 2026
BioCryst Pharmaceuticals (NASDAQ: BCRX) outlined a multi-pronged growth strategy at the JPMorgan Healthcare Conference, highlighting continued momentum for its hereditary angioedema (HAE) franchise, a
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
03:56pm, Monday, 12'th Jan 2026
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
–Excluding European ORLADEYO revenue for the full year 2025, preliminary 2025 ORLADEYO net revenue was $563 million (+43 percent y-o-y on a comparable basis)–
NEW YORK and NEW ORLEANS, Jan. 7, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:01am, Tuesday, 06'th Jan 2026
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted o
BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference
07:00am, Tuesday, 06'th Jan 2026
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 44th Annual J.P. Morgan Healthca
Assenagon Asset Management S.A. Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX
03:26am, Saturday, 20'th Dec 2025
Assenagon Asset Management S.A. reduced its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 14.6% during the undefined quarter, according to its most recent filing with the SEC. Th
Alkeon Capital Management LLC Cuts Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX
03:58am, Saturday, 13'th Dec 2025
Alkeon Capital Management LLC lowered its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 20.8% during the undefined quarter, according to the company in its most recent filing with the Secu
FDA expands approval of BioCryst's rare disease drug for use in young children
07:06am, Friday, 12'th Dec 2025
The U.S. Food and Drug Administration has expanded the use of BioCryst Pharmaceuticals' drug to include an oral pellet formulation for preventing hereditary angioedema attacks in children aged 2 to un
– ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older – -Oral pellet formulation provides child-friendly method of administration- –Showed early
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Thursday, 04'th Dec 2025
RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted f
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition
07:00am, Wednesday, 03'rd Dec 2025
RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has received early termination of the waiting period under the Ha
